ABIVAX press release
Abivax presents its 2022 half-year results and provides a progress report on its activities.
The global pivotal Phase 3 program with obefazimod in ulcerative colitis (UC) is progressing as planned with US Central Ethics Board approval and first patient enrollment expected in late September 2022.
The excellent results of the open-label maintenance study with obefazimod in moderate to severe UC demonstrate a “best-in-class” clinical remission rate of 55.3% for the entire population of 217 patients, after a year of daily oral administration of 50 mg of obefazimod.
Publication of a scientific article on the results of the induction study and the maintenance study after 48 weeks of treatment with obefazimod in the treatment of UC in the renowned peer-reviewed journal “Lancet Gastroenterology & Hepatology” .
Cash for the Company’s operating activities was reinforced in September by cross-over financing for a total amount of €49.2 million, extending the cash horizon until the end of the first quarter of 2023.